University of Maryland, Baltimore
Baltimore, Maryland, 21201, United States
NCT Number: NCT02692313
Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo endothelial function and atherothrombotic balance in humans. The specific aim of our study will be to determine the dose response effects of the key ANS counterregulatory hormone epinephrine on endothelial function, fibrinolytic balance and pro-atherogenic inflammatory mechanisms in healthy humans.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Early Phase 1
Baltimore, Maryland, 21201, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Physical Exam Exclusion Criteria
Screening Laboratory Tests Exclusion Criteria
Dose response of epinephrine infusion
Other names: Adrenaline
Placebo
Other names: Placebo
Time frame: From baseline (pre glucose clamp) to end of experiment (time 240 minutes- 2 hours post intervention (glucose clamp))
Measurements of FMD will be taken at baseline (pre intervention) and end of glucose clamp (post intervention) and the maximal % change determined
University of Maryland, Baltimore
Other
Hypoglycemia Associated Autonomic Dysfunction Dose Response of Epinephrine
Acronym: Epineprhine
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT05579743
Cardiovascular Diseases, Diabetes Complications
Baltimore, Maryland, United States
View Trial DetailsNCT06321029
Diabetes Complications, Diabetes Mellitus
Indianapolis, Indiana, United States
View Trial DetailsNCT04725630
Diabetes Complications, Diabetes Mellitus
Various Cities, Alberta, Canada
View Trial Details